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Aims Cardiac dysfunction is a severe complication of anthracycline-containing anticancer therapy. The outcome of
anthracycline-induced cardiomyopathy (AICM) compared with other non-ischaemic causes of heart failure (HF),
such as idiopathic dilated cardiomyopathy (IDCM), is unresolved. The aim of this study was to compare the survival
of AICM patients with an IDCM cohort followed at our centre from 1990 to 2016.
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Methods
and results
We included 67 patients (67% female, 50±15 years) with AICM, defined as onset of otherwise unexplained left ventricular
ejection fraction (LVEF) ≤50% following anthracycline therapy, and 488 IDCM patients (28% female, 55± 12 years). Patients
were followed with constantly optimized HF therapy, for 7.6± 5.5 and 8.1± 5.5 years, respectively. In both cohorts, 25% of
patients reached the combined endpoint of death/heart transplantation. Overall survival rates at 5 and 10 years were similar
(AICM: 86% and 61%, IDCM: 88% and 75%; P= 0.61), and so was cardiovascular survival (AICM: 91% and 76%, IDCM: 91%
and 80%; P= 0.373), also after 1:1 propensity matching (P= 0.27) and adjusting for age, LVEF and left ventricular size. A
trend toward higher all-cause mortality was present in AICM patients [hazard ratio (HR) 1.67, 95% confidence interval (CI)
0.95–2.92, P= 0.076]. No differences were observed between AICM and IDCM with regard to pharmacological HF therapy,
but AICM patients were less likely to receive devices (13% vs. 41.8% in IDCM, P< 0.001).
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Conclusion Cardiovascular mortality in patients with AICM did not differ from that of a matched IDCM cohort, despite
cancer-related morbidity and less prevalent use of devices. These data suggest that patients with AICM should
be treated with appropriate guideline-directed medical therapies similar to other non-ischaemic dilated cardiomy-
opathies.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Keywords Cardio-oncology • Anthracycline cardiotoxicity • Anthracycline cardiomyopathy •
Left ventricular dysfunction • Heart failure • Prognosis
Introduction
Earlier diagnosis and novel, effective treatments have led to a
remarkable increase in the number of cancer survivors, presently
estimated at 14.5 million in the USA1 and expected to reach
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.. 18 million by the year 2022.2 In many of these individuals,
long-term outcome is determined by cardiovascular (CV) mor-
bidity associated with cancer therapy-related toxicity.3 In the last
decade, the field of cardio-oncology has rapidly gained clinical rel-
evance and the resulting, widespread awareness has led to the
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adoption of preventive measures such as low-dose chemother-
apy regimens and early cardioprotective treatment.4 Yet, surpris-
ingly little information is known about the contemporary out-
come of chemotherapy-related heart diseases, including its most
prevalent form: anthracycline-induced cardiomyopathy (AICM).5–9
AICM, defined as a> 10% reduction in left ventricular ejection
fraction (LVEF), to levels <50%, compared with pre-treatment val-
ues, is associated with rates of heart failure (HF) that range from
5% to almost 26%, depending on the population and duration of
follow-up.8 AICM is common also in paediatric populations with
haematological and solid malignancies, and often presents as dilated
cardiomyopathy progressing to a restrictive phenotype.10,11
Despite a remarkable increase in the number of publications on
cardiotoxicity, limited data are available regarding the long-term
prognosis of cancer patients developing left ventricular (LV) systolic
dysfunction. When compared with other forms of cardiomyopathy,
AICM has been associated with a particularly poor prognosis,
with up to 60% of patients dying within 2 years of diagnosis.12
Of note, the 4-year mortality reported by Felker et al. in 2000
for doxorubicin-induced cardiomyopathy was 3.5-fold higher than
that of idiopathic dilated cardiomyopathy (IDCM).12 Following
this seminal study, progress has been limited and the long-term
outcome of AICM largely remains an open research and clinical
issue. Specifically, it is unclear whether the prognosis of AICM is
comparable with other non-ischaemic forms of cardiac dysfunction,
such as IDCM and therefore simply determined by the severity
of functional impairment, or whether its peculiar pathogenesis is
associated with an incremental prognostic impact. The present
retrospective analysis is aimed at comparing the characteristics, risk
factors and survival of two cohorts of AICM and IDCM patients,
systematically followed at our centre with the same management
strategies over the last 25 years.13
Methods
Study population
We retrospectively compared 67 patients with AICM, and 488 patients
with IDCM consecutively included in a systematic follow-up pro-
gramme at our centre from 1990 to 2016. The IDCM patients were
part of a previously described cohort.13 The clinical setting and man-
agement strategies adopted at out centre over this period have been
detailed in a previous publication.13 During the follow-up period,
three senior cardiologists with specific interest in primary cardiomy-
opathies and HF have been in charge of the patients. There is no
dedicated cardio-oncology unit at our centre, although a tight coop-
eration has progressively developed over the years, as awareness of
cardio-oncologic issues developed in the cardiological community.
Definitions
AICM was defined as a not-otherwise-explained LV systolic dysfunc-
tion, i.e. LVEF ≤50%, with or without dilatation, following anthracycline
administration and occurring in the absence of prior symptoms or clin-
ical and instrumental signs of heart disease.14 Specifically, each patient
had a demonstration of normal LVEF at screening evaluations prior to
anthracycline exposure, confirmed by at least two echocardiograms ..
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.. ≥6 months apart. All patients had a negative/inconclusive coronary
angiogram following diagnosis of AICM.
IDCM was defined by the presence of LV or biventricular dilatation
and systolic dysfunction in the absence of abnormal loading conditions
(hypertension, valvular disease) or coronary artery disease (CAD).14 In
total, among 747 patients evaluated during the same period, 259 were
excluded from the analysis because the LV dysfunction was deemed
secondary to CAD (n=125), hypertensive heart disease (n= 77),
valvular heart disease (n= 24), alcohol abuse (n=11), tachycardiomy-
opathy (n= 7), tricyclic antidepressant toxicity (n= 6), myocarditis
(n= 3), acquired immuno-deficiency syndrome (n= 3), connective
tissue disease (n=1), Tako-tsubo cardiomyopathy (n=1), and Lyme
disease (n= 1). Nine patients with mild elevation of arterial pressure
(World Health Organization grade I hypertension) were included.
Follow-up
Follow-up data were obtained from charts recorded during outpatient
controls that were programmed at 6-month intervals, unless more fre-
quently indicated. Clinical history, physical examination, 12-lead elec-
trocardiograms (ECG), standard chest X-ray, routine laboratory tests,
24-h Holter ECG, and M-mode, 2D and Doppler echocardiography
were recorded at baseline and over the follow-up. For the purpose
of the present analysis, follow-up was closed on 21 April 2016. For
patients who died or underwent orthotopic heart transplant (OHT),
these events were considered as the end of the follow-up, while
last clinical evaluation or telephone contact was taken into account
for patients lost to follow-up (i.e. not traceable by 21 April 2016).
Deaths were adjudicated by consensus between two senior investiga-
tors based on the evaluation of institutional documents and clinical
records. Use of drugs, implantable cardioverter defibrillator (ICD),
biventricular pacing for cardiac resynchronization therapy (CRT) or
ventricular assist device (VAD), was also recorded. Pharmacological
treatment was optimized following existing guidelines to maximal tol-
erated doses of angiotensin-converting enzyme inhibitors (ACEI) or
angiotensin receptor blockers (ARB), beta-blockers (BB) and miner-
alocorticoid receptor antagonists (MRA). Oral anticoagulation with
warfarin or, more recently, direct inhibitors, was initiated for car-
dioembolic prevention in patients with paroxysmal or permanent atrial
fibrillation.
Echocardiography
M-mode, 2D, and Doppler variables were measured in all patients
according to international guidelines15: left ventricular end-diastolic
(LVEDD) and left ventricular end-systolic diameters (LVESD) were
measured in M-mode, while volumes and LVEF were calculated
by 2D images from an apical four-chamber view, using the biplane
method. End-systolic left atrial dimension (LAD) was measured in the
antero-posterior linear diameter from the parasternal long-axis view.
All 2D echocardiographic parameters were indexed for body surface
area.16
Study endpoints
All-cause and CV deaths were considered as endpoints. For the
purpose of the study, OHT was considered as a CV death-equivalent
and included in the endpoint. Cancer-related death was defined as any
case in which a definite correlation between primitive cancer and death
was identified.
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Statistical analysis
Student’s t-test was used to compare continuous variables. Categor-
ical variables were compared by 𝜒2 test or Fisher’s exact test, as
appropriate. Mann–Whitney U test was used to compare numerical
variables with non-normal distribution, with prior normality assess-
ment by means of Shapiro–Wilk test. Wilcoxon signed-rank test
was used for paired comparisons (e.g. measurements on the same
patients before/after follow-up). The univariable survival estimates
were obtained using the Kaplan–Meier method. To avoid possible
bias due to unbalanced numbers of patients in the two cohorts, a
1:1 based propensity score matching was done. A non-parsimonious
logistic regression model was built in order to detect two sub-
groups of patients, according to type of cardiomyopathy, with com-
parable baseline data. Candidate matching variables were: age, sex,
New York Heart Association (NYHA) functional class, LVEDD, indexed
LVEDD (iLVEDD), indexed LAD (iLAD) and LVEF. With these two sub-
groups, each including 67 patients, survival analyses were performed
for all-cause and CV death. Proportional risk multivariable Cox regres-
sion analysis was used to evaluate the relationship between clinical
and instrumental baseline data and long-term all-cause or CV mortal-
ity. Age, LVEF and iLVEDD were included in the regression model as
independent variables. Risk proportionality was graphically assessed;
candidate predictors which did not met proportionality (namely, age)
were previously log-transformed. A P-value <0.05 was considered sta-
tistically significant. All analyses were performed with SPSS version 20.0
(SPSS Inc., Chicago, IL, USA).
Results
The mean follow-up from first diagnosis was 7.6± 5.5 years in
the AICM cohort and 8.1± 5.5 years in the IDCM cohort. The
mean age was 50±15 years in the AICM and 55± 12 years for
the IDCM group (Table 1). Non-Hodgkin’s (n= 39; 58.2%) and
Hodgkin’s lymphoma (n= 9; 13.4%) accounted for most indica-
tions to anthracycline therapy in the 67 AICM patients. Nine
patients (13.4%) had mild (grade I) hypertension, five (7.5%) dia-
betes, six (9.0%) hypercholesterolaemia and six (9.0%) were active
or previous smokers. By definition, a diagnosis of IDCM at our
centre implied the exclusion of coronary, hypertensive heart dis-
ease (with the exception of the above mentioned nine mild
grade hypertensive patients) and diabetes. With regard to dys-
lipidaemia and smoking, a similar prevalence to the AICM cohort
was observed (n= 76/15.6%, P= 0.128 and n= 80/16.4%, P= 0.97,
respectively). Fourteen patients (21.2%) had already received anti-
cancer chemotherapy prior to the most recent anthracycline expo-
sure and 29 (43.9%) received additional mediastinal or thoracic
radiotherapy. Time interval between last chemotherapy and AICM
diagnosis ranged from less than 1month to 23 years (median
10 years, interquartile range 3–48 years), with most cases diag-
nosed within 2 years of exposure (Figure 1). Almost three-quarters
(70%) of AICM patients developed CV complications (Table 1),
including HF (n= 43, 64%), thromboembolism (n= 11, 16%),
moderate-to-severe valve disease (n= 4; 6%, mainly mitral regur-
gitation), or atrial fibrillation (n=1; 1.5%). Two patients devel-
oped radiation-induced pulmonary fibrosis (3%). Of note, 14 (21%)
patients presented two or more of these complications during
follow-up. ..
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Table 1 Baseline characteristics
AICM
(n= 67)
IDCM
(n= 488)
P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Follow-up, years 7.6± 5.5 8.1± 5.5 0.408
Age at diagnosis, years 50±15 55±12 0.027
Male gender, n (%) 22 (32.8) 353 (72.3) <0.001
NYHA class I–II, n (%) 37 (55.2) 270 (55.3)
0.599
NYHA class III–IV, n (%) 30 (44.8) 218 (44.7)
LVEDD (mm) 56± 7 65± 8 <0.001
iLVEDD (mm/m2) 32± 5 35± 5 <0.001
iLAD (mm/m2) 22± 3 23± 4 0.128
LVEF (%) 39±10 33± 9 <0.001
AICM characteristics
Time from last CT to diagnosis, years 3.5± 5.6 – –
History of prior CTa, n (%) 14 (21.2) – –
Mediastinum/chest RT, n (%) 29 (43.9) – –
Oncological diseases
Non-Hodgkin’s lymphoma, n (%) 39 (58.2) – –
Hodgkin’s disease, n (%) 9 (13.4) – –
Leukaemia (lymphoblastic), n (%) 3 (4.5) – –
Breast cancer, n (%) 6 (8.9) – –
Otherb, n (%) 10 (15)
Cardiovascular and other complications
Heart failure, n (%) 43 (64.2) – –
Valve disease, n (%) 4 (6.2) – –
Arrhythmia (atrial fibrillation), n (%) 1 (1.5) – –
Thromboembolism, n (%) 11 (16.4) – –
Radiation-induced pulmonary fibrosis,
n (%)
2 (3.1) – –
No other complications, n (%) 18 (26.9) – –
Two or more complications, n (%) 14 (20.9) – –
Cardiological treatment during follow-up
ACEI, n (%) 45 (67.2) 409 (83.8) 0.003
ARB, n (%) 11 (16,4) 128 (26.2) 0.098
BB, n (%) 61 (91,0) 390 (79.9) 0.01
ACEI/ARB + BB, n (%) 52 (78.8) 381 (78.1) 0.896
MRA, n (%) 28 (42.4) 188 (38.5) 0.591
CRT, n (%) 4 (6.0) 89 (18,2) 0.009
ICD, n (%) 5 (7.5) 115 (23.6) 0.001
VAD, n (%) 0 (0.0) 2 (0.4) 1.000
Status and causes of death
Death (all causes), n (%) 13 (19.4) 100 (20.5) –
Cardiac (refractory HF), n (%) 7 (53.8) 29 (29.0) –
Cardiac (sudden death), n (%) 0 (0.0) 60 (60.0) –
Cancer related, n (%) 4 (30.8) 6 (6.0) –
Otherc, n (%) 2 (15.4) 5 (5.0) –
OHT, n (%) 4 (6.0) 21 (4.3) –
Lost at follow-up, n (%) 11 (16.4) 40 (8.2) –
Alive, n (%) 40 (59.7) 327 (67.0) –
AICM, anthracycline-induced cardiomyopathy; ACEI, angiotensin-converting enzyme inhibitor;
ARB, angiotensin receptor blocker; BB, beta-blocker; CT, chemotherapy; CRT, cardiac resyn-
chronization therapy; HF, heart failure; ICD, implantable cardioverter defibrillator; IDCM,
idiopathic dilated cardiomyopathy; iLAD, indexed left atrial diameter; iLVEDD, indexed left
ventricular end-diastolic diameter; LVEDD, left ventricular end-diastolic diameter; LVEF, left
ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NYHA, New York
Heart Association; OHT, orthotopic heart transplant; RT, radiotherapy; VAD, ventricular assist
device.
aFor the same or for a different disease.
bEndometrial (uterine) cancer (n= 3), osteosarcoma (n= 3), hepatocellular carcinoma (n= 2),
neuroblastoma (n= 2).
cNon-cardiac, non-cancer-related deaths.
Chemotherapy regimens
Typical anthracycline regimens, in most cases for haematological
cancers, are summarized in Table 2. On average, a cumulative dox-
orubicin dose of 273mg/m2 (range 160 to 300mg/m2) was admin-
istered. The initial exposure to previous anthracycline-containing
regimens was not included in the dose related to AICM onset.
© 2017 The Authors
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Figure 1 Time from last anthracycline-containing regimen
administration to diagnosis of anthracycline-induced cardiomy-
opathy (AICM) (years).
Comparison with the idiopathic dilated
cardiomyopathy cohort
The AICM and IDCM cohorts had comparable follow-up and
baseline functional status. However, AICM patients were younger
(50±15 vs. 55± 12, P= 0.027), predominantly females (67%, vs.
28%, P< 0.001), and had less severe LV dilatation and dysfunction
(Table 1). Indeed, they had lower baseline LVEDD and iLVEDD, and
higher LVEF than IDCM patients. Such differences disappeared after
1:1 propensity score matching based on age, sex, NYHA functional
class and echocardiographic parameters (Table 3).
Although BB were prescribed more often than ACEI to AICM
patients, there was no difference between the two groups in the
use of ACEI/ARB combined with BB (78.8% and 78.1% in AICM ..
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.. and IDCM, respectively, P= 0.896), nor of MRA (42.4% and 38.5%
in AICM and IDCM, respectively, P= 0.591). Devices were more
often implanted in IDCM than in AICM patients (18.2% vs 6%, for
CRT, P= 0.009; 23.6% vs. 7.5%, for ICD, P= 0.001, 0 vs. 0.4%, for
VAD, P= 1; Table 1). Evolution of HF therapies in AICM patients
over follow-up is described in Figure 2. The same data for IDCM
were found previously.13
Of note, LVEF significantly improved over follow-up in both
matched cohorts (AICM: from 39± 10% to 46± 10%, P< 0.001;
IDCM: from 39± 9% to 44± 10%, P< 0.001). Other rele-
vant echocardiographic parameters remained stable in AICM
patients (LVEDD: 56± 7.1mm vs. 56± 7.0mm, P= 0.601;
iLVEDD: 32± 4.6mm/m2 vs. 32± 3.9mm/m2, P= 0.531; iLAD
22± 3.0mm/m2 vs. 23± 3.3mm/m2, P= 0.104), whereas they
worsened significantly in those with IDCM (LVEDD: 58± 6.6mm
to 59± 6.9mm, P= 0.009; iLVEDD: 32± 4.4 to 34± 5.2mm/m2,
P= 0.004; iLAD 23± 5.0 to 24± 4.7mm/m2, P= 0.008; Figure 3).
Outcome
Of the 67 AICM patients, 11 (16%) were lost to follow-up after
attending clinic visits for a mean of 2.9 years, while 13 (19%) died
over a total of 509 patient/years. Of these, seven died of cardiac
causes, four of cancer-related complications, and two of other
causes. No arrhythmic or coronary deaths occurred in AICM
patients; 4 (6%) underwent OHT, 4.3± 4 years after the diagno-
sis of AICM, and were subsequently followed for 14.1± 3 years.
One of the OHT recipients died of refractory HF 9.5 years
after transplant. At 5 and 10 years, CV mortality-free survival
was 91% and 76%, while overall survival was 86% and 61%,
respectively.
Of the 488 IDCM patients, 40 (8%) were lost to follow-up after
attending outpatient visits for a mean of 6.6 years. Over 3950
patient/years, 100 patients (20%) died of sudden cardiac death
(n= 60), refractory HF (n= 29), cancer (n= 6), other non-cardiac
causes (n= 5). Twenty-one (4%) underwent OHT. At 5 and
10 years, CVmortality-free survival was 91% and 80%, while overall
survival was 88% and 75%, respectively.
Survival analysis
Survival rates in AICM and IDCM patients were comparable, both
for CV (log-rank 𝜒2 test 0.78, P= 0.373) and all-cause mortality
(log-rank 𝜒2 test 0.25, P= 0.616). At multivariable analysis, age,
iLVEDD and LVEF at diagnosis were significant predictors of CV
death, whereas the primary diagnosis was not (HR for AICM
vs. IDCM 1.22, 95% CI 0.62–2.40, P= 0.558; Table 4). There
was no difference in the outcome between AICM patients that
received concomitant radiation therapy and those who did not
(P= 0.34). There was a trend toward higher all-cause mortality
in the AICM cohort [hazard ratio (HR) vs. IDCM 1.67, 95%
confidence interval (CI) 0.95–2.92, P= 0.076; Table 4]. Survival
free of CV death remained comparable after 1:1 propensity score
matching (log-rank 𝜒2 test 1.08, P= 0.271; Figure 4).
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Table 2 Chemotherapy regimens
Schemes Composition n
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Fi2/89 Epirubicin 75mg/m2 (day 1), Vincristine 1.4mg/m2 (day 2;9) – Bleomycin 10mg/m2 (day 2–3,
8–10) – Cyclophosphamide 300mg/m2 (day 4–5, 11–12)+ Prednisone 40mg/m2 (day 1–12)
4
BAVEC–MiMA BCNU (carmustine) 100mg/m2 (day 1) – Doxorubicin 40mg/m2 (day 1) – Etoposide 60mg/m2 (day
1–4) – Vincristine 1.4mg/m2 (day 2) – Cyclophosphamide 600mg/m2 (day 3–4), Cytarabine 300mg/m2 (day
18), Methotrexate 150mg/m2 (day 19)+ Prednisone
4a
R–CHOP Rituximab 375mg/m2 – Cyclophosphamide 750mg/m2 (day 1) – Adriablastin 50mg/m2 (day 1) – Vincristine
1.4mg/m2 (day 1)+ Prednisone
9b
CHOP Cyclophosphamide 750mg/m2 (day 1) – Adriablastin 50mg/m2 (day 1) – Vincristine 1.4mg/m2 (day
1)+ Prednisone
15c
R–MACOP B Rituximab 375mg/m2 (weeks 1, 3, 5, 7, 9, 11) – Cyclophosphamide 350mg/m2 alternated to Adriablastin
50mg/m2 (weeks 1, 3, 5, 7, 9, 11) – Methotrexate 400mg/m2 (weeks 2, 6, 10)– Vincristine
1.4mg/m2/Bleomycin 10mg/m2 (weeks 4, 8, 12)
5
MEGA CHOP Cyclophosphamide 1200mg/m2 (day 1) – Adriablastin 70mg/m2 (day 1) – Vincristine 1.4mg/m2 (day
1)+ Prednisone
7
ABVD Adriablastin 25mg/m2 (day 1–14) – Bleomycin 10mg/m2 (day 1–14) – Vinblastine 6mg/m2 (day
1–14) – Dacarbazine mg/m2 (day 1–14)
7
Other Typical doses of Doxorubicin (in the context of various regimens) for breast cancer, ovarian cancer, osteosarcoma
and neuroblastoma: 40 to 60mg/m2 every 21 to 28 days; hepatocellular carcinoma: 75mg/m2 every 21 days
16
aOne patient received BAVEC–MiMA + mitoxantrone 10mg/m2.
bTwo patients received liposomal doxorubicin instead of adriablastin.
cSix patients received CHOP + sequential rituximab.
Table 3 Idiopathic dilated cardiomyopathy baseline characteristics in the 1:1 propensity score matched cohort
AICM
(n= 67)
IDCM
(n= 488)
IDCM cohort after 1:1
propensity score matchinga
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Follow-up, years 7.6 ± 5.5 8.1 ± 5.5 7.7 ± 5.3
Age at diagnosis, years 50 ±15* 55 ±12* 51 ±14
Male gender, n (%) 22 (32.8)* 353 (72.3)* 26 (38.8)
NYHA class I–II, n (%) 37 (55.2) 270 (55.3) 37 (55.2)
NYHA class III–IV, n (%) 30 (44.8) 218 (44.7) 30 (44.8)
LVEDD (mm) 56 ± 7* 65 ± 8* 57 ± 6
iLVEDD (mm/m2) 32 ± 5* 35 ± 5* 32 ± 5
iLAD (mm/m2) 22 ± 3 23 ± 4 23 ± 5
LVEF (%) 39 ±10* 33 ± 9* 39 ± 8
AICM, anthracycline-induced cardiomyopathy; IDCM, idiopathic dilated cardiomyopathy; iLAD, indexed left atrial diameter; iLVEDD, indexed left ventricular end-diastolic
diameter; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.
aCandidate matching variables were: age, sex, NYHA functional class, LVEDD, iLVEDD, iLAD, and LVEF.
*P< 0.05 before 1:1 propensity score matching.
Discussion
The present retrospective study was based on a well characterized
cohort of 67 patients with AICM systematically followed over a
mean of 7.6 years with optimized HF therapy, compared with IDCM
patients managed in the same setting and by the same team of
cardiologists with specific interest in primary cardiomyopathies and
HF. In line with the seminal report by Cardinale et al.,9 our data
show that AICM may be occasionally diagnosed decades after the
last anthracycline administration, but is largely recognized in the
first 2 years. As previously described17 and in contrast with the
well known preponderance of males in IDCM,13 we found a higher .
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.. baseline prevalence of females among AICM patients. Compared
with our IDCM patients, those with AICM showed higher LVEF
with smaller LV dimensions at diagnosis, in keeping with previous
reports indicating lesser degrees of LV dilatation as characteristic
of chemotherapy-induced cardiomyopathies.5,18,19
In our experience, AICM and IDCM patients showed similar
improvement in LVEF in response to optimized pharmacologi-
cal treatment, which was generally well tolerated (almost 80%
of our patients were treated with ACEI/ARB and BB). More-
over, we observed a comparable outcome for CV mortality in the
two groups, confirmed by 1:1 propensity score matching analy-
sis (adjusted for demographic, functional and echocardiographic
© 2017 The Authors
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Figure 2 Evolution in pharmacological and device therapy of the anthracycline-induced cardiomyopathy group from initial evaluation to end
of follow-up based on enrolment period. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BB, beta-blocker;
CRT, cardiac resynchronization therapy; ICD, implantable cardioverter defibrillator; MRA, mineralocorticoid receptor antagonist.
Figure 3 Changes in echocardiographic features over time in anthracycline-induced cardiomyopathy (AICM) and idiopathic dilated cardiomy-
opathy (IDCM) patients. FUp, follow-up; LAD, left atrial diameter; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection
fraction.
© 2017 The Authors
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Table 4 Multivariable Cox regression analysis
Adjusted
HR
95% CI P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Overall death
AICM vs. IDCM 1.67 0.95–2.92 0.076
Age (1 year increase) 1.02 1.01–1.03 0.007
iLVEDD (1mm/m2 increase) 1.06 1.02–1.09 0.004
LVEF (1% increase) 0.98 0.96–1.00 0.059
Cardiovascular death
AICM vs. IDCM 1.22 0.62–2.40 0.558
Age (1 year increase) 1.01 0.99–1.03 0.086
iLVEDD (1mm/m2 increase) 1.07 1.03–1.11 <0.001
LVEF (1% increase) 0.98 0.96–0.99 0.041
AICM, anthracycline-induced cardiomyopathy; CI, confidence interval; HR, haz-
ard ratio; IDCM, idiopathic dilated cardiomyopathy; iLVEDD, indexed left ven-
tricular end-diastolic diameter; LVEF, left ventricular ejection fraction.
Figure 4 Kaplan–Meier curves for cardiovascular mortality in
the anthracycline-induced cardiomyopathy (AICM) and idiopathic
dilated cardiomyopathy (IDCM) 1:1 matched populations.
parameters), despite an expected trend toward higher all-cause
mortality in AICM. Notably, the 5-year overall survival rate in
our AICM cohort (86%) appeared considerably better than that
reported by Felker et al. 17 years ago (<50%)12 and was substan-
tially equivalent to the 86.5% rate recently reported by Mazur
et al. in a small, but well characterized cohort of long-term adult
cancer survivors with AICM, followed for up to 8.5 years after
CRT/ICD implantation.20 This finding is even more remarkable con-
sidering that a significant proportion of our AICM patients received
thoracic radiotherapy and/or additional anticancer chemotherapy
prior to the most recent anthracycline exposure, and that use of
the less toxic liposomal anthracyclines was limited. ..
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.. Of note, a striking 64% of our AICM patients experienced signs
and/or symptoms of HF, despite constant surveillance and an opti-
mized treatment. In addition, almost three-quarters (73%) expe-
rienced other CV events or non-CV-related complications likely
related to cancer therapies (see Table 1). This finding corroborates
the recognition that CV toxicity in AICM patients extends beyond
LV dysfunction and HF, to include a variety of complications includ-
ing vascular disease, thromboembolism and arrhythmias.21
While the main mechanisms mediating anthracycline-mediated
cardiotoxicity are known,22,23 factors triggering individual predis-
position to AICM are unresolved. In some patients, the cardiotoxic
effect of antineoplastic drugs is likely enhanced by co-morbidities
and traditional CV risk factors (i.e. diabetes, dyslipidaemia, obesity,
smoking, hypertension, and CAD), suggesting an intrinsic frailty
of cancer survivors.24 Furthermore, a degree of individual genetic
predisposition appears likely, reflecting non-specific myocardial sus-
ceptibility to acquired disease. This view is supported by recent evi-
dence that rare truncating variants in the titin gene, not pathogenic
per se, are involved in peri-partum cardiomyopathy25 and that a
common deletion in MYBPC3 is associated with development of
HF in South Asian populations.26 Studies exploiting the potential
of next generation sequencing genetic techniques are warranted
to further investigate these issues.
The improved survival rate of AICM over time likely reflects a
more extensive use of potent HF therapies, aggressively pursued
at our centre in the last two decades13 and a greater awareness
and earlier recognition of AICM among specialists dedicated to
an increasingly close collaboration with the oncology teams. The
favorable response to neurohormonal blockade is in line with
previous reports on the effects of carvedilol and enalapril in AICM
patients with LVEF ≤45%, showing a 42% rate of responders
at 3 years (i.e. patients with LVEF recovery to values ≥50%),27
and with the more recent finding of a recovery rate> 80% in
patients treated with cardioprotective medications soon after
detection of AICM,9 confuting the dogma of the irreversibility of
anthracycline-induced myocardial damage.5 Of note, in the former
study,27 the proportion of responders was inversely related to
the delay between the end of chemotherapy and initiation of HF
treatment, and LVEF failed to recover whenever treatment was
delayed >6months. Consistently, cardiac event rates were lower
in responders than in partial or non-responders.27
In this perspective, advanced treatment options such as
CRT/ICD as well as VAD implantation or OHT, on top of an opti-
mized pharmacological HF therapy, represent reasonable strategies
for AICM patients and should be implemented when appropriate
according to international guidelines. This is an important clinical
message as aggressive management is often denied to cancer
survivors: for instance, we observed a lower use of implantable
devices in our AICM compared with our IDCM cohort (significant
for CRT/ICD). This may reflect, at least in part, a potentially erro-
neous assumption of reduced life expectancy in cancer patients,
even when they are potentially cured. Of note, none of the AICM
patients died suddenly, suggesting anyway that less frequent ICD
implantation did not negatively affect their outcome: this finding
is in line with recent published literature9 and corroborates
the recent findings by Mazur et al. about the similar burden of
© 2017 The Authors
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arrhythmias in AICM patients with CRT/ICD, compared with
both cancer and non-cancer patients suffering from ischaemic LV
dysfunction or IDCM20: interestingly, in this recent report, clinical
outcomes, including device therapy, OHT, and overall mortality,
did not differ between groups, as previously described.5,28,29 A
recent retrospective study also showed comparable outcome of
VAD and/or OHT in 17 patients with end-stage AICM vs. 51
patients with IDCM matched for co-morbidities and severity of
LV dysfunction, although a greater proportion of patients in the
AICM group developed recurrent or new primary cancer.30
We have acknowledged a number of limitations from this study,
starting with its retrospective nature, and the relatively small
cohort of AICM patients, this being only partly compensated by
the homogeneity of follow-up strategies and extended follow-up.
In addition, patients have been referred to our clinic over the
years following the detection of AICM, rather than during sys-
tematic screening for cardiotoxicity (the latter having been imple-
mented only recently at our Institution). Thus, intervals between
end of chemotherapy and diagnosis of LV dysfunction were vari-
able and may have influenced the final results. Finally, we acknowl-
edge the fact that a control cohort of cancer survivors with
non-anthracycline-related cardiomyopathy, would have been desir-
able, following the experience of Mazur et al.20
To date, the definition of chemotherapy-related LV dysfunction
is much debated. The definition of AICM used in our study (a LVEF
≤50% given at least two previous measurements of LVEF >50%)
differs somewhat from the current widely accepted definition of a
LVEF drop of 10% or higher to a value below 50%.31 While most
of our AICM patients likely fulfilled both criteria, we recognize that
the two definitions may not be fully comparable.
From the observations we made, there were no differences in
the AICM patients’ outcome between those receiving chemother-
apy and none receiving chemotherapy plus radiotherapy patients.
However, owing to the relatively small sample size, our results
should be interpreted with caution. Moreover, information about
radiation doses were not systematically collected as the study was
based on a historical cohort followed over decades. In the same
way the analysis of the prognostic impact of anthracycline dose
was attempted, but the study was definitely not powered to assess
differences among groups receiving diverse cumulative doses.
Finally, although patients with a history of significant CAD,
valvular disease or hypertensive heart disease were excluded from
the analysis, a substantial percentage of AICM patients showed CV
risk factors (i.e. mild hypertension and diabetes) that may have
influenced the natural history of the disease, potentially impacting
the correlation between cancer therapies and LV dysfunction in our
patients.
In conclusion, CV-related and overall mortality in patients with
AICM receiving optimized HF therapy did not differ from that
of a matched IDCM cohort, despite significant cancer-related
morbidity. These findings argue against the assumption of reduced
life expectancy in cardio-oncologic cohorts, compared with other
cardiac conditions, and support the implementation of dedicated
cardiological outpatient resources for cancer survivors. Given
similar prognosis of AICM with other non-ischaemic dilated forms
of cardiomyopathy, these patients should be treated aggressively ..
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.. and appropriately guided by contemporary HF clinical practice
guidelines. Larger, multicentre registry studies are needed to define
the clinical course and prognosis of AICM in the background of
modern chemotherapy regimens.
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